FEIBA is effective and well tolerated in major surgery

Case study: Forty-eight year old male patient with severe haemophilia A and an inhibitor1

Patient history:

  • Severe haemophilia A with inhibitors
  • Needed a total knee arthroplasty

Surgery:

  • Any surgical procedure in a patient with haemophilia is potentially life threatening and the risk of uncontrollable bleeding escalates when an inhibitor is present2-4
  • FEIBA prophylaxis used pre- and postoperatively
  • Loading dose of FEIBA followed by three doses every 8 h for 3 days and then tapered to daily dose

Outcome:

  • FEIBA was effective: The haemostatic outcome was good with no severe or unexpected complications
  • Tolerance to FEIBA during infusion was excellent*
  • Drainage of 750 mL of blood and a drop in haemoglobin concentration immediately following surgery, but did not require any transfusion

Case study: Bilateral total knee arthroplasty on young patient with inhibitors5

Patient history:

  • 26-year-old patient with inhibitors
  • Underwent bilateral total knee arthroplasty performed in 2 stages
  • Experienced severe degree of haemophilic arthropathy in both knees

Surgery:

  • Any surgical procedure in a patient with haemophilia is potentially life threatening and the risk of uncontrollable bleeding escalates when an inhibitor is present2-4
  • FEIBA administration was started with 100U/kg followed by second dose of 50U/ kg after 6 hours, continuing with a dose of 50U/kg every 12 hours, with a total of 40 doses
  • The joint scores before treatment and at follow-up were determined and the result was categorised into good, fair, and poor

Outcome:

  • Patient had a good outcome and no complications
  • FEIBA was effective and no adverse events were reported*

*Please refer to Prescribing Information for full side effect profile.
†Dosing recommendations could vary based upon your local prescribing information.

References

  1. 1. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FXVIII/IX: the updated Norwegian experience. Haemophilia. 2004;10(suppl 2):41-45.
  2. 2. Stine KC. Shrum D. Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or 8 with inhibitors. J Pediatr Hematol Oncol 2007: 29:216-221.
  3. 3. US National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. MASAC Document ·167. 2006.
  4. 4. Berntorp E, Gringeri A, Leissinger C, et al. New approaches to using FEIBA in the treatment of inhibitor patients. Semin Thromb Hemost. 2006, 32 (Suppl 2). 22-27.
  5. 5. Rodriguez-Merchan EC~ Quintana M~ Jimenez-Yuste V, et al. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007; 13:613-619.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more